India, May 21 -- BioMarin Pharmaceutical Inc. (BMRN) announced that its Phase 3 pivotal study CANOPY-HCH-3, of VOXZOGO (vosoritide) in children with hypochondroplasia met its primary and key secondary endpoints.
The randomized double-blind, placebo-controlled, multicenter trial enrolled 80 patients aged 3 to 17. Results showed a placebo-adjusted increase of 2.33 cm per year in annualized growth velocity (AGV) at week 52, exceeding the 1.57 cm per year improvement seen in VOXZOGO's prior achondroplasia study.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....